82095-23-6

Basic information

• Product Name: 1,25-dihydroxy-23-oxo-vitamin D3
• Synonyms: 1,25-dihydroxy-23-oxo-vitamin D3
• CAS NO: 82095-23-6
• Molecular Formula: C27H42 O4
• Molecular Weight: 0
• Mol File: 82095-23-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 598.6°C at 760 mmHg
• Flash Point: 329.9°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 7.93E-17mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: 1,25-dihydroxy-23-oxo-vitamin D3(CAS DataBase Reference)
• NIST Chemistry Reference: 1,25-dihydroxy-23-oxo-vitamin D3(82095-23-6)
• EPA Substance Registry System: 1,25-dihydroxy-23-oxo-vitamin D3(82095-23-6)

Safety Data

• Hazardous Substances Data: 82095-23-6(Hazardous Substances Data)

Usage

Chemical compound

A derivative of vitamin D3

Production

Synthesized in the kidney

Function

Regulates calcium and phosphate levels in the body

Classification

Potent steroid hormone

Mechanism of action

Acts as a transcriptional regulator

Receptor interaction

Binds to the vitamin D receptor

Gene regulation

Modulates the expression of genes involved in calcium absorption and bone mineralization

Additional effects

Immunomodulatory and anti-inflammatory properties

InChI:InChI=1/C27H42O4/c1-17(13-22(29)16-26(3,4)31)23-10-11-24-19(7-6-12-27(23,24)5)8-9-20-14-21(28)15-25(30)18(20)2/h8-9,17,21,23-25,28,30-31H,2,6-7,10-16H2,1,3-5H3/b19-8+,20-9-/t17-,21+,23-,24+,25-,27-/m1/s1

Upstream product

• 167892-97-9 1α,3β-bis[(t-butyldimethylsilyl)oxy]-20(S)-(n-propyl-23-oxo)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 167892-99-1 1α,3β-bis[(t-butyldimethylsilyl)oxy]-20(S)-(n-propyl-23-oxo)-9,10-secopregna-5(Z),7(E),10(19)-triene 
• 167892-96-8 1α-hydroxy-3β-[(t-butyldimethylsilyl)oxy]-20(S)-(n-propyl-23-oxo)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 167892-95-7 3β-[(t-butyldimethylsilyl)oxy]-20(S)-(propyl-23-oxo)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 167892-94-6 (R)-4-{(1R,3aS,7aR)-4-[2-[(S)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(E)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-pentan-2-ol 
• 167892-92-4 3β-[(t-butyldimethylsilyl)oxy]-20(S)-(cyanomethyl)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 167892-93-5 3β-[(t-butyldimethylsilyl)oxy]-20(S)-(formylmethyl)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 143884-24-6 (5E,7E,20S)-3β-(tert-butyldimethylsilyloxy)-20-(p-tolylsulfonyloxymethyl)-9,10-seco-5,7,10(19)-pregnatriene 
• 294176-94-6 1α,3β-bis[(t-butyldimethylsilyl)oxy]-23-oxo-9,10-secocholesta-5(Z),7(E),10(19)-trien-25-ol 

Relevant articles and documents

Synthesis and biological evaluations of C-23-modified 26,26,26,27,27,27-F6-vitamin D3 analogues

A convenient synthetic method which could allow flexible modification at C-23 of 26,26,26,27,27,27-hexafluoro-lα,25-dihydroxyvitamin D3 (3) has been developed. An effective construction of hexafluoroacetone (HFA) aldol part on the side chain of 10 was achieved by aldol reaction with HFA gas. This route is also attractive as an approach to diverse 26,27-modified vitamin D3 analogues. The preliminary biological activities of 23-modifed 26,27-F6 vitamin D3 analogues are evaluated. The potency of VDR affinities of the C-23-substituted analogues (keto group (4); OH group (5a,5b); fluorine atom (6a,6b); and oxetane ring (7a,7b)) was found to vary depending upon both the nature and stereochemistry of the substituents. In contrast, the HL-60 cell differentiation property was less varied than VDR affinity, and depended upon the nature rather than the stereochemistry of the substituents. Copyright (C) 2000 Elsevier Science Ltd.